Compare Stocks: AFMD, EGRX, CLRB, and INTS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18	$0.25	$0.07 ▼ $1.13	$2.92M	2.07	51.16 million shs	N/A
CLRB Cellectar Biosciences	$1.14 -4.2%	$2.18	$1.12 ▼ $5.03	$10.77M	0.58	380,542 shs	338,969 shs
EGRX Eagle Pharmaceuticals	$0.89 +0.6%	$0.81	$0.00 ▼ $1.80	$11.49M	0.83	7,615 shs	4,910 shs
INTS Intensity Therapeutics	$3.35 -0.9%	$3.97	$3.10 ▼ $43.50	$10.92M	2.81	39,753 shs	32,311 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	0.00%
CLRB Cellectar Biosciences	+0.85%	-15.00%	-48.71%	-52.59%	-76.10%
EGRX Eagle Pharmaceuticals	0.00%	-9.28%	-31.52%	+47.90%	-41.33%
INTS Intensity Therapeutics	-1.17%	-8.15%	-11.29%	-28.84%	-51.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18	$0.25	$0.07 ▼ $1.13	$2.92M	2.07	51.16 million shs	N/A
CLRB Cellectar Biosciences	$1.14 -4.2%	$2.18	$1.12 ▼ $5.03	$10.77M	0.58	380,542 shs	338,969 shs
EGRX Eagle Pharmaceuticals	$0.89 +0.6%	$0.81	$0.00 ▼ $1.80	$11.49M	0.83	7,615 shs	4,910 shs
INTS Intensity Therapeutics	$3.35 -0.9%	$3.97	$3.10 ▼ $43.50	$10.92M	2.81	39,753 shs	32,311 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	0.00%
CLRB Cellectar Biosciences	+0.85%	-15.00%	-48.71%	-52.59%	-76.10%
EGRX Eagle Pharmaceuticals	0.00%	-9.28%	-31.52%	+47.90%	-41.33%
INTS Intensity Therapeutics	-1.17%	-8.15%	-11.29%	-28.84%	-51.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	0.00	N/A	N/A	N/A
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	864.91% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	108.96% Upside

Current Analyst Ratings Breakdown

Latest AFMD, EGRX, CLRB, and INTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$5.00 ➝ $7.00
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/17/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$1.89 per share	N/A
EGRX Eagle Pharmaceuticals	$257.55M	0.04	$2.21 per share	0.40	N/A	∞
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$4.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	N/A	N/A	N/A	-7,836.26%	-193.84%	-107.24%	N/A
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	$1.18	0.75	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)

Latest AFMD, EGRX, CLRB, and INTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	CLRB Cellectar Biosciences	-$0.5565	N/A	N/A	N/A	$17.00 million	N/A
11/9/2026	N/A	EGRX Eagle Pharmaceuticals	$0.7330	N/A	N/A	N/A	$45.03 million	N/A
11/5/2026	Q3 2026	INTS Intensity Therapeutics	-$0.94	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
CLRB Cellectar Biosciences	N/A	6.66	6.66
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
INTS Intensity Therapeutics	0.01	5.00	5.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
CLRB Cellectar Biosciences	16.41%
EGRX Eagle Pharmaceuticals	85.36%
INTS Intensity Therapeutics	3.74%

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
CLRB Cellectar Biosciences	2.58%
EGRX Eagle Pharmaceuticals	28.90%
INTS Intensity Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	No Data
CLRB Cellectar Biosciences	11	9.45 million	9.21 million	No Data
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable

AFMD, EGRX, CLRB, and INTS Headlines

Recent News About These Companies

Intensity Therapeutics Inc. (NASDAQ:INTS) Stock Rated "Moderate Buy" by Wall Street Analysts

October 5, 2026 | americanbankingnews.com

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | prnewswire.com

Intensity's Q2 Loss Widens Marginally As Trials For Breast Cancer Drug Resume

September 4, 2026 | rttnews.com

Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3

August 11, 2026 | seekingalpha.com

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | prnewswire.com

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

August 4, 2026 | prnewswire.com

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

July 15, 2026 | prnewswire.com

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

July 1, 2026 | prnewswire.com

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why

May 27, 2026 | zacks.com

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

May 14, 2026 | prnewswire.com

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026 | prnewswire.com

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

May 1, 2026 | zacks.com

Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98

April 28, 2026 | msn.com

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

April 16, 2026 | zacks.com

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

April 15, 2026 | prnewswire.com

Intensity Therapeutics (INTS) price target decreased by 11.32% to 57.29

April 9, 2026 | msn.com

Intensity Therapeutics (INTS) price target decreased by 13.14% to 64.60

March 28, 2026 | msn.com

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

March 27, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, EGRX, CLRB, and INTS Company Descriptions

Affimed NASDAQ:AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Cellectar Biosciences NASDAQ:CLRB

$1.14 -0.05 (-4.20%)

Closing price 04:00 PM Eastern

Extended Trading

$1.15 +0.01 (+0.96%)

As of 06:24 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Eagle Pharmaceuticals NASDAQ:EGRX

$0.88 +0.01 (+0.57%)

As of 03:53 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Intensity Therapeutics NASDAQ:INTS

$3.35 -0.03 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$3.26 -0.09 (-2.69%)

As of 04:04 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AFMD, EGRX, CLRB, and INTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AFMD, EGRX, CLRB, and INTS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AFMD, EGRX, CLRB, and INTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, EGRX, CLRB, and INTS Company Descriptions

Affimed NASDAQ:AFMD

Cellectar Biosciences NASDAQ:CLRB

Eagle Pharmaceuticals NASDAQ:EGRX

Intensity Therapeutics NASDAQ:INTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AFMD, EGRX, CLRB, and INTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AFMD, EGRX, CLRB, and INTS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AFMD, EGRX, CLRB, and INTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, EGRX, CLRB, and INTS Company Descriptions

Affimed NASDAQ:AFMD

Cellectar Biosciences NASDAQ:CLRB

Eagle Pharmaceuticals NASDAQ:EGRX

Intensity Therapeutics NASDAQ:INTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools